A reported altitude cycling study found higher oxygen saturation but earlier exhaustion with acetazolamide. Here is the practical meaning for athletes over 35.
A report on a double-blind altitude study describes a striking contrast: preventive acetazolamide improved oxygen saturation but shortened cycling time to exhaustion in simulated hypoxia. Participants also reported greater effort with the medication than with placebo.
The report identifies the research as a study by Khazaei and Tadibi published in the International Journal of Sports Medicine on October 15, 2026. Its central finding concerns exercise performance under a specific laboratory protocol. The practical distinction is between preventing altitude illness and improving endurance performance.
For athletes preparing for a mountain event, those are separate decisions. A medication can have a role in illness prevention without functioning as an endurance aid.
According to the report, participants reached exhaustion sooner after taking acetazolamide than after taking placebo. The reported cycling times were:
The report describes this as about 32% less time to exhaustion in the tested protocol. The difference was statistically significant at p < 0.001.
Perceived effort also differed. Average Borg scale ratings were 14.5 with acetazolamide versus 11.8 with placebo. The report gives p = 0.002 for that comparison.
At the same time, oxygen saturation was higher with acetazolamide at rest in hypoxia and during exercise. It was also higher at exhaustion. Heart rate was reported as higher during exercise.
The important observation is the mismatch between the oxygen reading and the exercise result. Participants had higher oxygen saturation while sustaining the prescribed cycling effort for less time. Their effort ratings were higher as well.
That makes oxygen saturation and exercise performance distinct outcomes in this study. A more favorable reading did not correspond to a longer effort. For an athlete looking at the result, that distinction matters more than treating either measurement as a complete account of performance.
The report describes a randomized crossover study involving 12 men who were physical education students. Each participant completed both the acetazolamide and placebo conditions. The sessions were a week apart.
This design meant each participant served as his own comparison. The study therefore compared the conditions within the same people rather than relying entirely on differences between separate groups.
Before each test, participants received the assigned medication or placebo. They then sat for 30 minutes while breathing air containing 13% inspired oxygen. The report describes this as roughly equivalent to 3,800 metres.
Participants next cycled at 60% of peak power until exhaustion while remaining in the same hypoxic conditions. This was a constant-power test: the workload was prescribed and the measured outcome was how long participants sustained it.
That distinction is worth keeping clear. A time-to-exhaustion test measures the duration of a particular task. It is not the same measurement as the time needed to finish a race.
The study population was not a group of experienced endurance athletes or a masters-age sample. It included only men. The result therefore does not establish the response in women or in athletes aged 35 and older.
The test also involved acute simulated hypoxia rather than several days of acclimatization. Its short cycling effort does not establish what happens during a long mountain event. The reported 32% difference is not a forecast of a race slowdown or a basis for calculating a pace adjustment.
The study measured exercise duration rather than altitude-illness incidence or long-term adaptation. It therefore did not answer whether a participant's prevention needs were greater or smaller because of the performance result.
Earlier findings were not uniform either. The report describes a 2003 study that found lower maximal power with acetazolamide in hypoxia. It also describes a 2006 single-leg exercise study that found no significant endurance difference at simulated altitude.
Those studies used different participants and exercise protocols as well as different doses. They were not direct replications of the cycling test. Taken together, the report supports a specific finding under the tested conditions rather than a universal rule about exercise at altitude.
For masters-age athletes, the useful response is to separate the decisions involved in a mountain event. Illness prevention belongs in one discussion. Performance expectations belong in another.
Reendure's focus is on translating research into practical guidance while keeping long-term participation alongside immediate performance. Here, that means resisting the temptation to turn a physiological measurement into a promise about racing.
The report presents acetazolamide as a medication for preventing altitude illness rather than an endurance supplement. Its potential clinical purpose should not be judged solely by whether participants lasted longer in an exercise test.
In its account of the 2024 Wilderness Medical Society guideline, the report says acetazolamide was recommended for people at moderate or high risk of altitude illness. That recommendation addresses prevention. The cycling study addresses a performance outcome.
Neither question replaces the other. A discussion about whether medication is appropriate should address the athlete's prevention needs with a qualified clinician. A discussion about performance should avoid assuming that a higher oxygen reading means a stronger ride or run.
This is part of keeping fitness goals separate from health decisions. Competitive ambition remains important without becoming the sole basis for a medical choice.
The report's summary of the 2024 Wilderness Medical Society guideline emphasized gradual ascent as the primary preventive measure. Medication was described as an additional option when appropriate.
The practical planning priority is therefore the ascent itinerary rather than a hoped-for performance benefit from medication. Treating the journey upward as part of event preparation follows the guidance described in the report. It keeps prevention in the planning process rather than reducing it to something considered immediately before competition.
The competitive side can sit alongside a clear framework for deciding which races deserve priority. Race importance and medical prevention are different parts of preparation. Keeping them distinct makes the questions easier to discuss without asking a laboratory result to settle the whole trip.
The report notes that acetazolamide has contraindications and possible side effects. It lists tingling fingers, frequent urination and altered taste of carbonated drinks among those effects. It recommends discussing use with a doctor.
For an athlete considering altitude travel, that conversation is the place to assess whether the medication is appropriate. For an athlete with an existing prescription, questions about changing the plan belong with the prescribing clinician.
The performance finding is useful information to bring into that conversation. It is not a stand-alone reason to start or stop medication. The aim is a prevention decision grounded in the person's circumstances rather than a decision driven by an endurance headline.
The practical interpretation is narrower than that. The report supports treating acetazolamide as altitude-illness prevention rather than assuming it will improve endurance.
There is no need to build a new training block or fueling strategy around this finding. The useful change is conceptual: distinguish the oxygen measurement from the performance outcome. Then keep the ascent plan and clinician-guided prevention discussion central to preparation.
In the reported cycling study, preventive acetazolamide produced higher oxygen saturation alongside shorter time to exhaustion and greater perceived effort. The result challenges the assumption that a better oxygen reading necessarily means better endurance.
For endurance athletes over 35, the practical message is to keep prevention and performance separate. Prioritize gradual ascent as described in the reported guidance. Make medication decisions with a qualified clinician rather than treating acetazolamide as an endurance aid.
The evidence supports a clearer understanding of the medication's role. It does not require a wholesale change to training, recovery or nutrition.
Follow ReEndure for practical insights on endurance training, recovery, nutrition and healthy aging. Stay connected for new articles, research led guidance and ideas to help you perform better for longer.
Read practical ideas on endurance training, recovery, nutrition and healthy aging to keep progressing for years to come.
Read the Blog